OrbiMed’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

OrbiMed’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-66,000	Closed	-$6.65M	–	145
2018 Q4	$6.65M	Buy	+66,000	New	+$6.84M	0.12%	95

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

OrbiMed's ICPT Position: Q1 2020 in Review

OrbiMed sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2020, closing a stake of 22,800 shares — an estimated $2.83M sold.

OrbiMed first reported a position in ICPT in Q2 2013 and held it in 21 quarters. The position peaked at $572M in Q1 2014. 188 funds tracked by Wall St. Rank hold ICPT as of Q1 2020.

OrbiMed reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
OrbiMed sold 22,800 Intercept Pharmaceuticals, Inc. shares in Q1 2020, an estimated $2.83M.
OrbiMed first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 21 quarters.
OrbiMed's Intercept Pharmaceuticals, Inc. position peaked at $572M in Q1 2014.
188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2020.

Based on OrbiMed's 13F filing for Q1 2020, filed 15 May 2020.